Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

American Express

Coca-Cola

Kroger

Realty Income Corp

Philip Morris

Tractor Supply

Dividends are a signal to investors of a profitable business. Typically the most successful companies pay investors to own their stock.

7 No-Frills Dividend Stocks for Your Must-Own List

The latest trial over claims that Johnson & Johnson's talc products cause cancer ended in a mistrial on Tuesday, as a Florida state court jury said it could not agree on a verdict.

Latest J&J talc trial ends with hung jury

Johnson & Johnson (NYSE:JNJ ) Cowen 44th Annual Health Care Conference Call March 4, 2024 11:10 AM ET Company Participants Hani Abouhalka - Company Group Chairman, Robotics and Digital, Johnson & Johnson MedTech Conference Call Participants Joshua Jennings - Cowen Joshua Jennings We are going to get started with our next fireside chat session. We are thrilled to be moving down the medical devices track with executive from Johnson & Johnson's MedTech business unit.

Johnson & Johnson (JNJ) Management presents at Cowen 44th Annual Health Care Conference (Transcript)

The approval is based on data from a late-stage study wherein treatment with J&J's (JNJ) Rybrevant plus chemotherapy reduced the disease-progression risk or death by 61% in certain NSCLC patients.

J&J (JNJ) Secures Full FDA Nod for Rybrevant in Lung Cancer

AbbVie

Emerson Electric

Genuine Parts

Lowe's

Procter & Gamble

Investing in dividend kings is about keeping things simple. A distinguishing feature of these companies is a rock-solid balance sheet that allows them to demonstrate unwavering commitment to building shareholder value.

Secure Your Future: 7 Dividend Kings with Solid Growth Potential

Amgen

Amazon

Boeing

Caterpillar

Salesforce

Cisco Systems

Chevron

Disney

Dow Inc

Goldman Sachs

Intel

McDonald's

Microsoft

NIKE

UnitedHealth Group

Verizon

"The Dow® [adds a stock] if the company has an excellent reputation, demonstrates sustained growth, and is of interest to a large number of investors. Sector representation is also a consideration.”–DowJones&Co. The highest-yield 10 stocks are March's Dogs of the Dow: GS, JNJ, KO, AMGN, CSCO, IBM, CVX, DOW, MMM, and VZ. They only averaged a 4.15% annual yield. Thirty Dow stocks represent nine of eleven sectors. DowJones tracks utilities as a separate index and omits real estate. Broker top-ten target-estimated March net-gains ranged 12.35%-25.79%, topped by BA 2/29/24.

March Dogs Of The Dow: Buy 1; Watch 4

Johnson & Johnson has been leaning on acquisitions lately to strengthen its portfolio of products. The company expects to grow at an annual rate of around 5% or better until the end of the decade.

Will Johnson & Johnson Be a Trillion-Dollar Stock by 2030?

Approval is based on results from the Phase 3 PAPILLON study, which demonstrated RYBREVANT® plus chemotherapy reduced the risk of disease progression or death by 61 percent versus chemotherapy alone in patients with previously untreated NSCLC with EGFR exon 20 insertion mutations National Comprehensive Cancer Network ® (NCCN ®) updated its NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ®) to recommend amivantamab-vmjw (RYBREVANT®) plus chemotherapy as a preferred first-line regimen for patients with NSCLC with EGFR exon 20 insertion mutations RARITAN, N.J. , March 1, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that following a priority review, the U.S. Food and Drug Administration (FDA) has approved RYBREVANT® (amivantamab-vmjw) in combination with chemotherapy (carboplatin-pemetrexed) for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations as detected by an FDA-approved test.1 This FDA action converts the May 2021 accelerated approval of RYBREVANT® to a full approval based on the confirmatory Phase 3 PAPILLON study.

RYBREVANT® (amivantamab-vmjw) in Combination With Chemotherapy Is the First FDA Approved Therapy for First-line Treatment of Patients With Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

The U.S. health regulator on Friday approved Johnson & Johnson's therapy in combination with other chemotherapies for the first-line treatment of a type of lung cancer.

FDA approves J&J's combination therapy for a type of lung cancer

Costco

Target

While the equities sector roars higher, it's never a bad idea to consider stocks to buy for a down market. No, I'm not prognosticating an imminent calamity.

Don't Panic! 7 Smart Stocks to Buy if the Markets Take a Tumble.

Altria

Dividend stocks have handsomely outpaced the average annual return of non-payers over the past 50 years. Wall Street's Dividend Kings -- companies that have increased their payouts for at least 50 consecutive years -- provide some of the safest income on the planet.

Want $1,000 in Ultra-Safe Annual Dividend Income? Invest $19,000 Into the Following 3 Time-Tested Dividend Kings.

Johnson & Johnson now has a slimmer business model than before. It may be launching a handful of products this year as well.

Johnson & Johnson Stock Has 33% Upside, According to 1 Wall Street Analyst

Abbott Labs

UnitedHealth is a central cog in U.S. healthcare. Johnson & Johnson is arguably the world's most financially secure company.

Nearing Retirement? These Stocks Are as Cautious as They Come

Johnson & Johnson (JNJ) concluded the recent trading session at $160.98, signifying a +0.12% move from its prior day's close.

Johnson & Johnson (JNJ) Rises But Trails Market: What Investors Should Know

Apple

Broadcom

JPMorgan Chase & Co

There are many paths to profit on Wall Street but one of the best strategies is investing in dividend stocks. Over long periods dividend-paying stocks have outperformed those that don't pay one.

7 Dividend Stocks Every Investor Should Own to Survive a Market Crash

Con Ed

Federal Realty Investment Trust

Kenvue

Northwest Natural Gas

Its expertise includes creating urban, mixed-use neighborhoods like: Santana Row in San Jose, California Pike & Rose in North Bethesda, Maryland Assembly Row in Somerville, Massachusetts Federal Realty's 102 properties include approximately 3,300 26 million square feet tenants and over 3,100 residential units.

5 Virtually Unknown Dividend Kings That Generate Strong Passive Income

Johnson & Johnson (NYSE: JNJ) reported its Q4 results last month, with revenues and earnings marginally above the street estimates. The company reported revenue of $21.4 billion and adjusted earnings of $2.29 per share, compared to the consensus estimates of $21.0 billion and $2.28, respectively.

Should You Pick Johnson & Johnson Stock At $160?

PepsiCo

Dividend stocks are an ideal way to build wealth. Whether you are just starting your investment journey or looking for ways to enjoy steady returns on your investment, investing in dividend stocks is a smart move.

3 Dividend Stocks That Are Too Good to Ignore: Q1 Edition

Alphabet

Palantir Technologies

SoFi Technologies

This earnings season has been explosive. Several stocks hit all-time highs, including Nvidia (NASDAQ: NVDA ).

News for Johnson & Johnson Stock (JNJ)